Search Results

By Animesh Pardanani, MBBS, PhD  / January 1 2012

Ruxolitinib for Myelofibrosis Therapy: A Good Start but a Long Road Ahead

Following a priority review process for orphan diseases, ruxolitinb (Jakafi) recently became the first drug to receive FDA approval for the treatment of intermediate- and high-risk myelofibrosis. Discovery in 2004 of the JAK2V617F mutation in a significant proportion of patients with...